Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab. by Nugue, Guillaume et al.
Monitoring monoclonal antibody delivery in oncology:
the example of bevacizumab.
Guillaume Nugue, Marie Bidart, Marie Arlotto, Mireille Mousseau, Franc¸ois
Berger, Laurent Pelletier
To cite this version:
Guillaume Nugue, Marie Bidart, Marie Arlotto, Mireille Mousseau, Franc¸ois Berger, et al..
Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab.. PLoS
ONE, Public Library of Science, 2013, 8 (8), pp.e72021. <10.1371/journal.pone.0072021>.
<inserm-00854640>
HAL Id: inserm-00854640
http://www.hal.inserm.fr/inserm-00854640
Submitted on 27 Aug 2013
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Monitoring Monoclonal Antibody Delivery in Oncology:
The Example of Bevacizumab
Guillaume Nugue1,3, Marie Bidart1,2,3, Marie Arlotto1,3, Mireille Mousseau1,2,3, Franc¸ois Berger1,2,3,
Laurent Pelletier1,2,3*
1Grenoble Institut des Neurosciences, Grenoble, France, 2Centre Hospitalier Universitaire, Grenoble, France, 3Universite´ Joseph Fourier, Grenoble, France
Abstract
Developing therapeutic monoclonal antibodies paves the way for new strategies in oncology using targeted therapy which
should improve specificity. However, due to a lack of biomarkers, a personalized therapy scheme cannot always be applied
with monoclonal antibodies. As a consequence, the efficacy or side effects associated with this type of treatment often
appear to be sporadic. Bevacizumab is a therapeutic monoclonal antibody targeting Vascular Endothelial Growth Factor
(VEGF). It is used to limit tumor vascularization. No prognosis or response biomarker is associated with this antibody, we
therefore assessed whether the administration protocol could be a possible cause of heterogeneous responses (or variable
efficacy). To do this, we developed a bevacizumab assay with a broad sensitivity range to measure blood bevacizumab
concentrations. We then analyzed bevacizumab concentrations in 17 patients throughout the first quarter of treatment. In
line with previously published data, average blood concentrations were 88+/227 mg/L following the first dose
administered, and 213+/2105 mg/L after the last (6th) dose administered. However, the individual values were scattered,
with a mean 4-fold difference between the lowest and the highest concentration for each dose administered. We
demonstrated that the bevacizumab administration schedule results in a high inter-individual variability in terms of blood
concentrations. Comparison of assay data with clinical data indicates that blood concentrations above the median are
associated with side effects, whereas values below the median favor inefficacy. In conclusion, bevacizumab-based therapy
could benefit from a personalized administration schedule including follow-up and adjustment of circulating bevacizumab
concentrations.
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Introduction
Over the last decade, significant advances have been made in
the care of cancer patients. Oncology’s therapeutic arsenal has
been expanded through the emergence of monoclonal antibodies
(mAbs). mAbs are produced by a single B cell immortalized by
fusion with a myeloma cell, in a process developed by Kohler in
1975 [1]. In contrast to chemotherapy, which has remarkable
effects but significant toxicity, mAbs have the advantage of being
highly specific. They thus represent a targeted therapy, and are
likely to have limited toxicity and be applicable as part of a
personalized medicine strategy.
The Vascular Endothelial Growth Factor (VEGF) pathway was
recognized as a key regulator of angiogenesis in. This led to the
development of several VEGF-targeting agents, including bev-
acizumab (AvastinH, Roche-Genentech) [3]. Bevacizumab is a
humanized anti-VEGF monoclonal antibody, which neutralizes
VEGF. It thus inhibits angiogenesis and limits tumor growth [2,3].
Bevacizumab was the first anti-angiogenesis agent approved by the
Food and Drug Administration (FDA) for the treatment of
metastatic colorectal cancer in 2004 [4]. Since then, bevacizumab
has received additional FDA approval, including for glioblastoma
in 2009 [5].
Despite an overall benefit of bevacizumab in the treatment of
different tumors, clinical outcomes can be highly variable, with
some patients responding remarkably well to anti-angiogenic
therapy, while others do not [6,7]. Furthermore, side-effects such
as vascular disorders (bleeding, phlebitis, embolism) often lead to
definitive cessation of the treatment [8].
Because of this heterogeneous response, the real clinical impact
of bevacizumab remains unclear. For example, although bevaci-
zumab delays the progression of brain and breast cancers, it does
not improve overall survival [9,10].
One way of assessing the clinical efficacy of a drug is to
characterize its pharmacokinetics (PK). The antibody concentra-
tion and the kinetics of monoclonal antibody elimination are
modulated by several parameters (body weight, gender, liver
function) [11,12]. Thus, modulation of the PK of bevacizumab
could explain the inter-individual variability observed in patients.
Roche-Genentech have reported a mean half-life of bevacizumab
close to 20 days [13], however, large individual differences were
noted, with a half-life ranging between 11 and 50 days. In spite of
this, a standardized administration protocol is recommended [13].
Presumably, inter-individual variability in bevacizumab PK could
cause variable responses to the treatment. When treatment is
administered every other week, a patient for whom the half-life is
50 days would present an excess of circulating antibody from the
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second dose. This could be the reason for the vascular disorders
noted as side effects during therapy. In contrast, a patient for
whom the half-life is only 11 days will rapidly clear bevacizumab,
and this could impede treatment efficacy. Since the dawn of the
therapeutic mAb era, personalized treatment regimes have not
been applied, despite significant PK variability. Rapid assays must
therefore be developed to monitor concentrations in patients’
blood during treatment. This will allow the dose of the drug to be
adapted to the patient’s own pharmacokinetic profile. This is
essential if a real therapeutic effect is to be observed. A first step in
this process requires precise monitoring of bevacizumab concen-
trations throughout treatment. In this article, we describe an assay
based on suspension array technology [14]. The assay we have
developed is sensitive, rapid, accurate and adapted to clinical use.
The approach was validated by evaluating bevacizumab blood
levels in a cohort of brain- and breast-cancer patients treated with
bevacizumab.
Materials and Methods
Patients
Patients included in this study were men and women between
39 and 79 years old, treated with bevacizumab for brain- or
breast-cancer (n = 17). For the pharmacodynamic study, patients
with breast cancer were excluded (n = 3) and clinical data was
confidential for one brain tumor patient. Analysis was therefore
performed on 13 glioma patients. All patients provided written
informed consent for participation in this study
(CBR.GSI.ENR.003 V4, Grenoble University Hospital). The
informed consent document and the study as a whole were
approved by the hospital ethics committee (COMITE DE
PROTECTION DES PERSONNES).
Treatment and Samples
Bevacizumab was intravenously infused at 10 mg/kg of body
weight every two weeks. Blood samples were taken just before
bevacizumab infusion.
Bead Coupling
Recombinant human VEGF (2–10 mg; PHC9393; Invitrogen)
was conjugated to Bio-Plex COOH Pro Magnetic beads (Bio-
Rad). Briefly, beads were washed once in washing buffer (PBS,
0.05% tween-20, pH 7.4). Beads were incubated under slow
rotation with activation buffer (0.1 M NaH2PO4, pH 6.2), 5 mg/
ml S-NHS (P24510; Thermo Scientific) and 5 mg/ml EDAC
(P77149; Thermo Scientific) for 20 min at room temperature
(RT), and washed twice in PBS. Beads were then incubated for 2
hours with rhVEGF in PBS, with mixing by rotation at RT. Beads
were washed once in washing buffer and incubated for 30 mins in
blocking buffer (PBS, 1% BSA, 0.05% Sodium Azide, pH 7.4).
Beads were stored at 4uC in storage buffer (PBS, 1% BSA, 0.05%
Sodium Azide, pH 7.4).
Bevacizumab Assay Procedure
Bevacizumab was assayed by suspension array technology.
Briefly, 5,000 VEGF-beads were deposited per well in Bio-Plex
pro flat-bottom plates (Bio-Rad). Beads were washed twice with
75 ml of wash buffer (PBS-0.05%Tween-20, pH 7.4) on a wash
station (Bio-Plex Pro II; Bio-Rad). Beads were then incubated with
appropriately PBS-diluted serum for 30 min under slow agitation
at RT. Beads were then washed three times on a wash station and
incubated with phycoerythrin-conjugated (PE) anti-human IgG
(Sigma-Aldrich) for 30 min under slow agitation at RT. Beads
were once again washed three times on a wash station. PE binding
was measured on a Bio-Plex 220 (Bio-Rad) and analyzed using
Bio-Plex Manager 5.0 software (Bio-Rad). Bevacizumab used as
standard was purchased from Roche-Genentech, and stored at
4uC.
Assay Validation
Assay characterization and validation was performed according
to the guidelines for method validation in medical biology [15].
Briefly, the lowest limit of quantification (LLOQ) was calculated as
the mean signal background plus three standard deviations. The
highest limit of quantification (HLOQ) was calculated as the mean
maximum fluorescence minus three standard deviations. The
coefficient of variation (CV) was calculated for each concentration
point by dividing the mean by the standard deviation. The
inaccuracy (or bias) was calculated for each concentration point as
the mean minus the value divided by the value.
Statistical Analysis
Graphpad Prism software (version 4)was used for statistical
analysis. The bevacizumab concentration parameter was com-
pared for each patient sample using the Kruskal-Wallis test.
Statistical significance was defined as p,0.05.
Results
Developing and Validating the Bevacizumab Assay
The first step of our work was to develop a bevacizumab assay
using a suspension array. This required covalent linkage of
rhVEGF to beads which could then be used to trap bevacizumab
in samples. Bevacizumab binding was quantified using a PE-
conjugated secondary antibody directed against human IgG.
In line with the instructions for the Bio-Plex amine coupling kit
(Bio-Rad), we adapted several parameters (number of beads per
well, amount of rhVEGF coupled to beads, secondary antibody
concentration) to optimize the assay. The maximum of this range
corresponds to twice the maximum expected bevacizumab
concentration in serum. For our assay, we chose to coat beads
with 10 mg rhVEGF (see material and methods section), to use
5,000 beads per well and 1,000-fold diluted sample.
Next, we qualified the assay by defining LHOQ, LLOQ, CV
and inaccuracy (or bias) (Table 1). These parameters were defined
on a series of 15 independent assays (figure 1). The CV varied
from 6 to 25% over the 0.001 mg/L to 6 mg/L range and
remained below 15% from 0.008 to 6 mg/L. According to the
guidelines for biomedical assays, the assay is valid only with a CV
below 15%. Our assay is therefore valid from 0.008 to 6 mg/L.
The LLOQ and LHOQ were determined as 0.008 and 1 mg/L,
respectively, and the bias defining accuracy was 1.48% (+/21.83).
Variable Bevacizumab Pharmacokinetics in Patients
Once we had developed and validated our assay, we measured
bevacizumab concentrations in patient sera. Seventeen patients
were analyzed over the first three months of bevacizumab
treatment (6 complete treatment cycles; Table 2). Blood samples
were taken just before bevacizumab administration every second
week. Before treatment was initiated, no bevacizumab was
detected in serum. As expected, following repeated administration,
the serum concentration reached a steady state. At the sixth dose,
the concentration was precisely 95% of the plateau value (figure 2).
If the half-life for bevacizumab is 20 days (Roche-Genentech data)
and 10 mg/kg is administered at each dose, the plateau for
bevacizumab concentration should shift from 203 mg/mL to
330 mg/L, just before and just after administration, respectively.
The concentration measured at the plateau just prior to
Pharmacokinetics of Bevacizumab
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administration was 213+/2105 mg/L, which is very close to the
theoretical value.
When we consider individual data rather than the mean
concentration for the population, we observed extensive disper-
sion. For example, concentrations were between 54 and 149 (88+/
227) mg/L and 73 and 411 (213+/2105) mg/L for the first and
the last doses, respectively. Thus, the ratio between the lowest and
highest value was 2.8 and 5.6, respectively. This is representative
of all the results, which have an overall ratio of 4.3.
Identifying Serum Bevacizumab Levels as a
Pharmacodynamic Marker
Patients were then classed in three groups according to clinical
data: patients with side effects, non-responders and good
responders. The side effects group (n = 5) was defined as patients
with vascular complications, in particular epistaxis, gastrointestinal
hemorrhage and high blood pressure. One case of phlebitis was
also associated with the highest serum bevacizumab level
(355 mg/L). The non-responder group (n = 4) presented residual
angiogenesis, as assessed by MRI after three months of treatment.
Patients who did not have any residual angiogenesis nor side
effects were defined as good responders (n = 4). Remarkably, low
serum bevacizumab concentrations were associated with a lack of
efficacy, while high concentrations were associated with side effects
(figure 3). Comparison of mean variances confirmed that the mean
concentrations were significantly different in the three clinical
groups (p,0.05). When the mean concentrations were examined
for each dose, the groups appeared significantly different for doses
5 (p,0.05) and 6 (p,0.01). For both these doses, the side effects
group was associated with the highest concentrations (254+/
213 mg/L and 333+/211 mg/L, respectively); the non-respond-
er group had the lowest concentrations (153+/213 mg/L and
200+/235 mg/L, respectively); and the responder group was
associated with intermediate concentrations (216+/237 mg/L
and 218+/20 mg/L, respectively). Thus, serum bevacizumab
concentration appears to be a useful clinical pharmacodynamic
marker.
Discussion
Whatever the biological status of patients, mAb therapies are
nearly always applied using a standardized administration
protocol, without personalization. This study aimed to determine
whether adapting bevacizumab administration only on the basis of
the patient’s physical parameters (weight) could lead to treatment
discrepancies.
Figure 1. Bevacizumab assay calibration. Fluorescence intensity was measured on 15 independent assays over a large bevacizumab range (0–
6 mg/mL).
doi:10.1371/journal.pone.0072021.g001
Table 1. Validation of bevacizumab assay (n = 15).
bevacizumab (mg/L) CV (%) Bias (%)
6 6.03 NA
2 6.43 4.51
0.7 6.86 3.11
0.2 6.99 0.04
0.07 10.03 20.6
0.025 12.87 2.25
0.008 12.15 0.01
0.003 20.28 0.47
0 24.92 NA
The coefficient of variation (CV) was calculated for each concentration point by
dividing the mean by the standard deviation. The assay was validated for CVs
under 20% (bold). Inaccuracy (bias) was calculated (mean minus value divided
by value) only over the validated range.
NA: not applicable.
doi:10.1371/journal.pone.0072021.t001
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To do this, we first developed a bevacizumab immunoassay
using suspension array technology for rapid, sensitive measure-
ment of this mAb in patient’s serum. Our bevacizumab assay can
be completed in 2 hours, which is a significant improvement over
the 6 hours required for a similar ELISA [7]. The ELISA is
accurate and reproducible between 5 and 75 mg/L [7]. Our test is
also accurate and reproducible, but over a more clinically relevant
quantification range (0.008 to 6 mg/L) with a CV below 15%.
Our multiplex bevacizumab assay is therefore readily adaptable to
clinical practice. Moreover, in contrast with ELISA, our assay can
be used for multiplexed assays [14]. For example, it would be
Figure 2. Evolution of blood bevacizumab concentrations over the first 3 months of treatment. Points represent the mean bevacizumab
concentrations for the 17 patients (+/2 SD).The dotted line corresponds to the theoretical bevacizumab concentration in a 70-kg patient, with
treatment by 7 repeat administrations of 10 mg/kg every other week. The theoretical value was calculated using the bevacizumab half-life reported
by Roche-Genentech (20 days).
doi:10.1371/journal.pone.0072021.g002
Table 2. Patient characteristics.
Patient Age Sex Weight Disease Treatment
Bevacizumab at
70 days (mg/L)
1 78 F – Breast cancer Paclitaxel-bevacizumab 93
2 60 M 64 Glioma Bevacizumab 380*
3 49 F 57 Glioma Irinotecan-bevacizumab 252
4 58 M 75 Glioma Irinotecan-bevacizumab 205
5 56 M 69 Glioma Irinotecan-bevacizumab 229*
6 52 M 79 Glioma Irinotecan-bevacizumab 166
7 41 M – Glioma Irinotecan-bevacizumab 283*
8 50 M 74 Glioma Irinotecan-bevacizumab 121*
9 61 M 71 Glioma Bevacizumab 313
10 56 F 102 Breast cancer Paclitaxel-bevacizumab 131
11 59 M 63 Glioma Irinotecan-bevacizumab 213
12 58 M – Glioma Irinotecan-bevacizumab 289
13 53 M 79 Glioma Irinotecan-bevacizumab 350
14 51 F 72 Breast cancer Paclitaxel-bevacizumab 348
15 58 M 86 Glioma Irinotecan-bevacizumab 355
16 56 F 82 Glioma Irinotecan-bevacizumab 175
17 64 M 82 Glioma Irinotecan-bevacizumab 267
Serum bevacizumab concentrations were determined at the plateau (70 days; values labeled with an asterisk correspond to 56 days). M: Male; F: Female.
doi:10.1371/journal.pone.0072021.t002
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highly relevant to simultaneously measure bevacizumab and its
circulating target, VEGF.
This assay was then used to monitor bevacizumab PK in a
cohort of 17 glioma or breast cancer patients treated with
bevacizumab. The mean concentration for our cohort was close to
the previously reported theoretical concentration with intravenous
infusion every two weeks at 10 mg/kg body weight (figure 2).
However, we observed a wide range of serum bevacizumab
concentrations with the same administration regime. For example,
the concentrations ranged from 54 to 149 mg/L before the second
dose, and from 73 to 411 mg/L before the final (sixth) dose was
administered. These results emphasize that patients treated by
applying the same protocol (10 mg/kg of body weight) do not
benefit from the same efficacy of treatment.
Limited PK and pharmacodynamics data has been published
on bevacizumab, and most of the information available is supplied
by Roche-Genentech [13]. Moreover, inter-individual PK vari-
ability is generally not taken into account since PK is measured as
the mean for a population, and is then used to determine which
dose should be given to all individuals. We must now reevaluate
this parameter for bevacizumab therapy. The PK parameters for
bevacizumab are similar to those for IgG, for which body weight is
the covariate with the greatest influence on interpatient variance
[16]. This supports a treatment schedule design based on body
weight. However, gender, which is associated with a difference in
muscular mass; tumor burden, which correlates with a faster
bevacizumab clearance [17]; or serum glutamic oxaloacetic
transaminase (SGOT), indicative of impaired liver function, could
also be assessed as covariates. In the Roche-Genentech study,
slight differences in clearance were noted as a function of these
factors [13]. However, other factors should also be studied. For
example, recycling of the neonatal Fc receptor (FcRn) is a
common rescue pathway for monoclonal antibodies that leads to a
long half-life [18]. In 2008, Lu et al. [6] described a mathematical
model to address the variability of bevacizumab PK based on five
parameters (body weight, gender, albumin, alkaline phosphatase,
and SGOT). They found weight and gender to be the covariates
with the greatest influence on bevacizumab PK [6]. Nonetheless,
these mathematical models have limits as they cannot take all
possible covariates into account. For example, serum VEGF
concentrations could affect bevacizumab clearance. To check this,
we measured serum VEGF levels, but no correlation with PK was
found (data not shown). In addition, mathematical models require
numerous parameters, which are not always easy to provide in a
clinical context. For simple optimization of bevacizumab sched-
uling and to eliminate covariation, we suggest using our
bevacizumab immunoassay as a global biomarker of PK.
Beyond the description of inter-individual heterogeneity, our
results raise the issue of how PK correlates with clinical outcome.
This study thus questions the relevance of an administration
protocol for a monoclonal antibody not associated with a
companion test to monitor its PK for each patient as part of a
personalized therapeutic approach. Our preliminary data strongly
suggest that low bevacizumab blood levels (less than 200 mg/L
just prior the 6th administration) - associated with residual
angiogenesis - could compromise treatment efficacy, whereas a
high level (more than 250 mg/L just prior the 6th administration) -
close to the toxic dose - could increase the occurrence of side
effects (hemorrhage, phlebitis) (Figure 3). We observed that the
maximum treatment efficacy/side effects ratio appeared with a
bevacizumab concentration between 200 and 250 mg/L. This
therapeutic index has to be more precisely determined using a
reinforced cohort, Such a deepened study would also refine the
pharmacodynamics results, allowing to discriminate patients
groups earlier during the treatment. Thus, the serum bevacizumab
level is a candidate pharmacodynamic marker for this therapy,
and should be further validated to allow tailored treatment
schedules to be developed. In contrast with Lu et al. [6], our data
Figure 3. Serum bevacizumab levels as a function of treatment efficacy. (&) mean value for patients with side effects (n = 5); (m)mean value
for patients with residual angiogenesis (n = 4); (¤) mean value for patients responding favorably to treatment (n = 4).
doi:10.1371/journal.pone.0072021.g003
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revealed no link between tumor burden and serum clearance.
Thus, further studies are required, for example, with blood
samples from clinical trial patients.
In line with the well-known relationship between PK param-
eters and efficacy, our results, and others [8], suggest that
bevacizumab concentrations could be a prognostic/response
biomarker. Using PK measurements as a companion test for
personalizing mAb administration could thus eliminate the current
treatment bias. Patients with low levels of circulating bevacizumab
could be given an increased drug dose on subsequent administra-
tion, while patients with high levels could receive less. The
procedure for defining the correction factor to be applied to the
doses administered should be determined in future studies using
mathematical models, and with data from a larger patient cohort.
There is a huge need for prognostic biomarkers or response
indicators when treating patients with bevacizumab. Currently,
progression-free survival at 6 months is between 36% and 46% for
bevacizumab-treated patients with glioblastoma [9,11], but no
benefit in terms of overall survival is observed. Oncologists are
thus faced with a situation where they do not know the correct
optimum dose for patients. Because of this, mAbs are currently
prescribed as a function of maximal therapeutic dose, similar to
chemotherapy. Our results suggest that patients could benefit from
an early test to adapt the dose, which could improve therapeutic
efficacy while decreasing side effects. The clinical endpoints for
trials to define doses should move to more functional endpoints,
for example considering efficacy. This would shift the focus from a
maximum therapeutic dose to an optimal biological dose [19].
In conclusion, the fundamental role of bevacizumab in the
therapeutic arsenal in oncology, the highly variable patient
responses, and the relative lack of data on the PK for this
monoclonal antibody suggest that measuring blood bevacizumab
levels may be clinically relevant. We have developed a robust and
sensitive bevacizumab assay which is rapid and could be suitable
for use in clinical routine as part of personalized treatment.
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